LabPsycho @LabPsych0

Can I bring Monte Rosa Therapeutics @MonteRosaTxrecent Cover Article in SCIENCE magazine to life? Use it as the basis for nanomining to accelerate drug discovery? See below and then see my post below that.

Nanomining Neosubstrates Using Molecular Dynamic Simulations and @MonteRosaTx MRT-3486. LabPsycho’s Artificial Artificial IntelligenceTM (A2.I.), VMD, Colab, Openmm, Alpha Fold, Python, SwissParam and simulated on Google Colab using NVIDIA T4 GPU DOI: 10.1126/science.adt6736

$TNGX My Molecular Dynamic Simulation of TNG462 bound to PRMT5·MTA Refs: J. Med. Chem. 2025, 68, 5, 5097–5119 @TangoTxOncology Molecular ensemble built in part using VMD, Colab, Openmm, Alpha Fold, Python, SwissParam & LabPsycho’s Artificial Artificial IntelligenceTM (A.^2 I.)

Shown below is my Molecular Dynamic Simulation of @TangoTxOncology TNG908 bound to PRMT5·MTA Refs: 1. DOI: 10.1021/acs.jmedchem.4c03067 2. Ensemble built in part using VMD, Colab, Openmm, Alpha Fold, Python, SwissParam and LabPsycho’s Artificial Artificial Intelligence (A2.I.)

Details of the "Molecular Dynamic Simulation of CFT8919 Molecular Glue in Complex with Cereblon and EGFR" are shown in this video. Methodology and references are in the description of the video. youtu.be/NZCPeihFmts?si… via @YouTube @C4Therapeutics

$CCCC Molecular Dynamic Simulation of C4's CFT8919 drug (or something close to it). Shown is CFT8919 in complex with Cereblon, a component of the CRL4A E3 ubiquitin ligase complex and epidermal growth factor receptor (EGFR). See below for more details.

Depicted is the initial structure I created for the first? molecular dynamics (MD) simulation of C4 Therapeutics’ @C4Therapeutics investigational compound CFT8919. The eclectic, hypothetical model shows putative structure of CFT8919 bound to Cereblon and a mutant form EGFR.

$CRVS LabPsycho’s Artificial Artificial Intelligence (A.^2 I.) ™ is exponentially better than A.I. and predicts $CRVS will make two large spikes and be over $11.21 by Nov 04, 2024

$CNTX @Context_Tx CEO really needs to show one of these world's first molecular dynamic simulations of Claudin-6 Antibody interacting with its receptor posted last year at these upcoming investor conferences. It could be parlayed into another huge money raise. Martin - call me.

$CTMX Ugh...CTMX has tarnished my (so far excellent) A^2.I. record twice now....trying for a third time here. LabPsycho’s Artificial Artificial Intelligence (A.^2 I.) ™ is exponentially better than A.I. and predicts $CTMX will make a +/- 30% move by Nov 12, 2024

LabPsycho’s Artificial Artificial Intelligence (A.^2 I.) ™ is exponentially better than A.I. and predicts $CTMX will be $1.28 by Oct 08, 2024

Perhaps a partnership will be announced by Q3?

The Earnings Edge @TheEarningsEdge

a year ago

Perhaps a partnership will be announced by Q3?

3 3 10 11K 4

$CTMX Cytomx has been beaten down like so many other biotechs the past 3-4 months seems to be coming off the bottom. Trading volume remains significant / high suggesting to me a +/- 25% move possible within the next 2 weeks.

$BCAB Bioatla moving up - July 25th They present Clinical Program and Pipeline updates. Will a potential partnership be announced at this time / later in the year or not at all?

$XLO Today, 7 million shares trade @$1 without moving the needle. Suggests to me this drift down to 1 has been orchestrated for weeks. Why?

Molecular ensemble of @senseibio SNS-101-Fab in complex with hypothetical construct of VISTA. Eclectic structure of VISTA with transmembrane domain built in part using VMD, openmm, Alpha Fold, python + my Artificial Artificial Intelligence (A^2.I. – exponentially better than A.I.

Molecular Dynamic Simulation of @senseibio SNS-101-Fab in Complex with VISTA Molecular ensemble of SNS-101-Fab in complex with VISTA was built based on PDB ID: 8TBQ [1]. Simulations were done using CHARMM_GUI in Google Colab using T4 GPU. 1. Nat Commun 15, 2917 (2024)

Targeted protein degradation using KronosBio KB-0742 warhead using my Bait-N-Switch Linker bound to CDK9 and E3 Ligase. My proposed application of KRON's KB-0742 has potential to be a 100X Force Multiplier in augmenting specificity for CDK9 in cancer cells and

further turbocharges the molecule by bringing catalytic mechanism of action into the mix, hence increased efficacy at a lower dose to help reduce any adverse side effects. My own Artificial Intelligence plus billions of in silico calculations demonstrates proof of concept.

Key to my linker is that it can become slightly positively charged in the acidic environment of tumor cells (selecting for tumor vs. normal cells) and is 3D engineered to parlay the (mostly) unique acid residue position on CDK9 (vs other CDK's) to preferentially select for CDK9.